132 related articles for article (PubMed ID: 18398027)
1. Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Kendall A; Anderson H; Dunbier AK; Mackay A; Dexter T; Urruticoechea A; Harper-Wynne C; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):855-63. PubMed ID: 18398027
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
3. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
[TBL] [Abstract][Full Text] [Related]
4. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Harper-Wynne C; Ross G; Sacks N; Salter J; Nasiri N; Iqbal J; A'Hern R; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):614-21. PubMed ID: 12101108
[TBL] [Abstract][Full Text] [Related]
5. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
8. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Frank DH; Kimler BF; Fabian CJ; Ranger-Moore J; Yozwiak M; Bartels HG; Alberts DS; Bartels PH
Breast Cancer Res Treat; 2009 Jun; 115(3):661-8. PubMed ID: 19125322
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
11. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Kendall A; Dowsett M
Endocr Relat Cancer; 2006 Sep; 13(3):827-37. PubMed ID: 16954432
[TBL] [Abstract][Full Text] [Related]
12. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
15. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Miller WR; Larionov A; Anderson TJ; Evans DB; Dixon JM
Pharmacogenomics J; 2012 Feb; 12(1):10-21. PubMed ID: 20697427
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Chow LW; Yip AY; Loo WT; Toi M
Cancer Lett; 2008 Apr; 262(2):232-8. PubMed ID: 18248884
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
Nordman IC; Dalley DN
Breast J; 2008; 14(6):562-9. PubMed ID: 19000052
[TBL] [Abstract][Full Text] [Related]
19. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
